Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro, Inc. - Common Stock (NQ:ALZN)

0.9951 UNCHANGED
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alzamend Neuro, Inc. - Common Stock

< Previous 1 2 3 Next >
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects 
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in PTSD subjects 
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Bipolar Disorder subjects 
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjects 
From Alzamend Neuro, Inc.
Via GlobeNewswire
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease 
Via PressReach
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
October 15, 
Via PressReach
Alzamend Neuro Announces Completion of a Novel Head Coil by Tesla for Measuring Brain Structure Lithium Levels in Five Upcoming Phase II Clinical Trials at Massachusetts General Hospital
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
October 10, 
Via PressReach
Alzamend Neuro to Present at the Sequire Investor Summit
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease 
Via PressReach
Exposures Product Safety
Alzamend Neuro to Present Non-Clinical Data Update at the Society of Toxicology 2025 Annual Meeting and ToxExpo
From Alzamend Neuro, Inc.
Via Business Wire
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
Exposures Product Safety
Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder
Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by... 
Via PressReach
Exposures Product Safety
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be... 
Via PressReach
Exposures Product Safety
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves... 
Via PressReach
Exposures Product Safety
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease
Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical... 
Via PressReach
Exposures Product Safety
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
Alzamend Neuro, Inc. (Nasdaq:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease 
Via PressReach
Exposures Product Safety
Alzamend Neuro Issues Letter to Stockholders
From Alzamend Neuro
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease 
Via PressReach
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer’s Disease
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.